Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637455 | 1.00 | STS (0.60) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL29676710 | 1.00 | STS (0.60) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL28720984 | 0.93 | STS (0.65) | STSJAK2JAK1GPR119KDM4E | |
| SCHEMBL3413600 | 0.91 | STS (0.56) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL3789110 | 0.84 | SMN1; SMN2 (0.56) | JAK2JAK1GAASMN1; SMN2 | |
| SCHEMBL29426286 | 0.82 | STS (0.58) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL30758095 | 0.82 | STS (0.58) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL20503925 | 0.81 | JAK2 (0.55) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL942191 | 0.81 | JAK2 (0.55) | STSJAK2JAK1GPR119USP30 | |
| SCHEMBL697850 | 0.81 | JAK2 (0.55) | STSJAK2JAK1GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| EP-3517535-B1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-11059805-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| US-20200339541-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| EP-3517535-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-31 | — | — | EP | disclosed |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339541-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
| US-11059805-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | STS 315/4885JAK2 12/4885JAK1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.